HRTX - Want to Make Money in Biotech? Do This First
Biotech investors live and die by the binary news events generated by the drugmakers they invest in. Heron Therapeutics (NASDAQ: HRTX) , for instance, is awaiting a decision from the Food and Drug Administration about its candidate HTX-011 for use in post-operative pain. Likewise, Alkermes (NASDAQ: ALKS) expects an FDA decision on its schizophrenia and bipolar treatment ALKS3831 on or before June 1.
In this video from Motley Fool Live , recorded on Mar ch 2 9 , Fool.com contributors Brian Orelli and Keith Speights discuss the best ways to keep abreast of news that biotech companies release. They discuss websites that aggregate that information, but investors with a small number of biotechs in their portfolios might be best off just keeping abreast of what those companies are up to through their websites and SEC disclosures.
For further details see:
Want to Make Money in Biotech? Do This First